Plain-English translation of NCT06690476 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer vaccine called IPM514 to see if it can help people with advanced esophageal cancer whose tumors have stopped responding to standard treatment. Researchers want to understand how safe the medication is, how your body processes it, and whether it can help slow or shrink tumors. Depending on the stage of the trial, you might receive IPM514 alone, or combined with other cancer-fighting drugs including an immunotherapy drug and chemotherapy.
Current treatments for advanced esophageal cancer don't work well enough for everyone, and many patients' cancers come back or stop responding over time. This trial explores whether this new vaccine approach can offer a better option by training your immune system to recognize and attack cancer cells.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication into your muscle over several weeks, with visits spaced one to three weeks apart. Depending on which part of the trial you join, treatment could last several months and may include additional intravenous drugs given at a hospital or clinic. You'll have regular blood tests, imaging scans, and check-ins with the research team to monitor how you're tolerating the treatment and whether your tumor is responding.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China